On January 12, 2026, Zymeworks announced a series of executive appointments, promotions, retirements and board additions designed to strengthen its governance and operational capabilities. Investment veteran Brian Cherry joined the Board of Directors, bringing over 25 years of private equity experience and involvement in transactions totaling more than $25 billion in enterprise value. Mark Hollywood was promoted to Executive Vice President and Chief Operating Officer, expanding his remit beyond Technology and Manufacturing Operations to include Quality and Alliance Management. Dr. Sabeen Mekan will transition to Chief Medical Officer on February 1, succeeding Dr. Jeff Smith who will retire and remain as an adviser during a handover period. Five new vice presidents and three senior vice presidents were named across Human Resources, Finance, Corporate Development, Translational Sciences, Investor Relations, Corporate Communications, Treasury and Regulatory Affairs, underscoring the company’s emphasis on leadership depth in preparation for its next growth phase. The company has initiated a search for a permanent Chief Financial Officer, with CEO Kenneth Galbraith serving as Acting CFO until a replacement is secured.

Zymeworks reported that its Phase 3 HERIZON-GEA-01 trial of Ziihera in first-line HER2-positive gastric and gastroesophageal junction adenocarcinoma achieved a median overall survival exceeding two years, consistent across PD-L1 expression subgroups and with a manageable safety profile. This result positions Ziihera for potential regulatory approval in multiple regions and unlocks up to $440 million in near-term milestone payments under existing collaboration agreements—an amount that significantly surpasses the company’s recent quarterly revenue of $27.6 million. Investors should note that the trial’s positive outcome strengthens the case for Ziihera as a new standard-of-care therapy and materially enhances Zymeworks’ projected royalty and cash-flow streams from its licensed oncology portfolio.